ClinicalTrials.gg
RecruitingNCT06072768SMART-RAUpdated Nov 19, 2026

Dynamic Treatment Regiments for Glucocorticoid Tapering

A Phase 2 interventional study of 15-day taper prednisone and 150-day taper prednisone in Rheumatoid Arthritis, sponsored by VA Office of Research and Development. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by VA Office of Research and Development · Phase 2, Interventional, and Health services research

How we know

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Mar 2023, registered Oct 2023).
  • Started Mar 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
200
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 975 studies in Arthritis, Rheumatoid with a site in United States — 82 open to participants now, 121 under way, 7 of them phase 3. Arthritis, Rheumatoid · United States.

Planned enrollment
302nd of 771
200 · median 120
Started
2023
with 29 others
Phase 2
215 of 975
12 open now
Primary completion
2029-03
later than 92 of 120 live
Registered
906th of 975
by date

Among the 975 studies in Arthritis, Rheumatoid with a site in United States, this one is the 302nd largest by planned enrollment of the 771 interventional ones that give a count, is one of 30 that started in 2023, is one of 215 in phase 2, reaches primary completion later than 92 of the 120 other live ones, and was the 906th registered.

Arthritis, Rheumatoid

3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

82 of the 975 studies in Arthritis, Rheumatoid with a site in United States are open now. Recruiting first, the newest first:

77 more — sign in →

All 82 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 975 studies in Arthritis, Rheumatoid with a site in United States, or all of them as a file.
02

Study summary

The purpose of this clinical trial is to better understand how people with rheumatoid arthritis (RA) respond to gradual dose reduction, or "tapering", of steroid medications like prednisone. Some people with RA have symptoms when steroid dose is reduced, while others don't. This trial will look at different patient characteristics, including levels of inflammation in the body, differences in the way the brain processes sensory information, and certain hormone levels, to help researchers better understand why different people have these different responses to steroid tapering.

The hypotheses include:

  • Greater or equal to ( ) 30% of participants in each arm will develop taper intolerance (either subjective, objective, or both) during the study period
  • Greater or equal to 60% of participants will reduce Glucocorticoid dose by at least 5 Milligrams per day during the study period
Read the detailed description

This trial was changed, so that participants could participate remotely without coming into the clinic. For participants coming into the clinic, the clinical disease activity index (CDAI) will be used to measure objective intolerance to tapering.

For remote participants, the Rheumatoid Arthritis Disease Activity Index (RADAI) will be used instead of the CDAI.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Disease-modifying anti-rheumatic drug
  • Oral prednisone
  • Dose reduction
  • Tapering
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Ability to read and speak English to allow for written and patient-reported outcomes measures.

  • Provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Ability to take oral medication and be willing to adhere to the study intervention regimen
  • Diagnosis of rheumatoid arthritis by a medical provider, confirmed by checking medical records.
  • Current use of an RA treatment regimen of both oral prednisone and 1 other Food and Drug Administration-approved disease-modifying antirheumatic drug (DMARD), with no change in this therapy over the past 90 days

    1. Eligible DMARDs include the following: hydroxychloroquine, sulfasalazine, methotrexate, leflunomide, etanercept, adalimumab, infliximab, golimumab, certolizumab pegol, abatacept, tocilizumab, sarilumab, rituximab, tofacitinib, baricitinib, upadacitinib
    2. Patients enrolling in the 15-day taper must be taking 7.5mg/day oral prednisone
    3. Patients enrolling in the 150-day taper must be taking 5mg/day oral prednisone

Exclusion criteria

Exclusion Criteria:

Current or recent (past year) use of systemic (oral, intravenous, or intramuscular administration) >2 weeks for an indication other than RA, to reduce risk of adverse health outcomes related to worsening of the indicated condition

  • Patients with greater than moderate RA activity as determined by the Clinical Disease Activity Index or by rheumatologist assessment, given high likelihood of taper failure in this population due to increased RA activity alone.
  • Pre-existing primary or secondary adrenal insufficiency diagnosed by a physician, given high risk of worsening with prednisone taper
  • Treatment with another drug or intervention within 90 days
  • Pregnancy
  • Self-reported medical or psychiatric conditions that in the judgment of study personnel would preclude participation in this study (e.g., schizophrenia, , psychosis, suicidal ideation, history of substance abuse; note that stable anxiety and depression are NOT exclusions)
  • Current, recent (within the last 6 months), or habitual use of artificial nails or nail enhancements. (Artificial nails can influence pressure pain sensitivity at the thumbnail);
  • Any impairment, activity, behavior, or situation that in the judgment of the study team would prevent satisfactory completion of the study protocol
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Health services research
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    15-day taper prednisone

    This will be for 30 days. Participants will be allocated to the 15-day strategy preferentially until enrollment goals have been met; once completing the 15-day strategy, many participants will also be eligible to complete the 150-day strategy, and may subsequently enroll in it if they wish. Participants that are not eligible for the 15-day strategy, but are eligible for the 150-day strategy, will be enrolled in the 150-day strategy.

    Drug: 15-day taper prednisone

  • Experimental
    150-day taper prednisone

    This will be for 180 days. Participants who are not eligible for the 15-day strategy, but are eligible for the 150-day strategy, will be enrolled in the 150-day strategy.

    Drug: 150-day taper prednisone

Interventions

  • Drug15-day taper prednisone

    The 15-day taper group will assess the effect of an approximately 50% oral prednisone dose reduction over 15 days, and will be followed for an additional 15 days after the last dose reduction.

  • Drug150-day taper prednisone

    The 150-day taper group will assess the effect of reducing oral prednisone by 1 milligram (mg) every 30 days over 150 days, and will be followed for an additional 30 days after the last dose reduction.

06

What researchers measure

Primary outcomes

  1. Number of participants with subjective taper intolerance

    Subjective intolerance, the first point when a participant replies elects to stop glucocorticoid taper due to associated symptoms. This will be assessed using a one-question questionnaire with binary "yes" and "no" responses.

    Time frame: Day 30 (15-day taper) or day 180 (150-day taper group)

  2. Number of participants with objective taper intolerance

    The first point when a participant develops any one of: increased RA activity (either clinical disease activity index \[CDAI\] increase of \>2, or rheumatoid arthritis disease activity index \[RADAI\] of 1.5); RA flare (either CDAI increase of \>1, or RADAI increase of \>1 at a time when participant classifies as flaring; Clinical adrenal insufficiency.

    Time frame: Day 30 (15-day taper) or day 180 (150-day taper group)

  3. Net glucocorticoid dose reduction

    The difference (in mg/day) between a participant's prednisone dose at enrollment, and either (1) the dose at which participants first develop taper intolerance, or (2) the dose at the end of study involvement, if participants do not develop taper intolerance.

    Time frame: Day 30 (15-day taper) or day 180 (150-day taper group)

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Mar 2029, 71 months after the start.

Of 42 non-industry phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 49. This study's planned 71 months is above that.

Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2023
First posted
Oct 10, 2023
StartActual
Mar 9, 2023
Primary completionEst.
Mar 1, 2029
CompletionEst.
Mar 1, 2030
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers and contact details
1 update, last Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Minor edits only
    + 2 other changes: identifiers and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06072768
Responsible party
Sponsor
First posted
Oct 10, 2023
Start date
Mar 9, 2023
Primary completion
Mar 1, 2029 (estimated)
Completion
Mar 1, 2030 (estimated)
Last update
Nov 19, 2026

Study contacts

Olivia B Dickinson, BA
Contact
Olivia.Dickinson@va.gov
(734) 548-2987
Beth Wallace, MD MSc
principal investigator · VA Ann Arbor Healthcare System, Ann Arbor, MI

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion